180 Life Sciences Corp. Overview
Pro stress-test →180 Life Sciences began as a biotechnology company and pivoted toward iGaming, then further evolved by adopting an Ethereum treasury strategy and rebranding to operate as ETHZilla, developing an accumulation vehicle for Ether (ETH). Through a treasury policy focused on ETH, it aims to hold Ether as the principal asset in its treasury reserve.
Strategic Profile
Pro stress-test →The company closed a $425 million private placement and raised $565 million total through private placements and convertible notes to implement its Ethereum treasury strategy. It has accumulated 94,675 ETH valued at approximately $419 million with $187 million in cash, with Electric Capital serving as external asset manager implementing an on-chain yield generation program.
Competitive Landscape
Pro stress-test →Other biotech companies have shifted toward becoming crypto treasury companies, this time focusing on Ethereum. The company competes against traditional cryptocurrency investment vehicles and ETH staking platforms. Legacy biotech IP represents niche positioning in neuroinflammation and fibrotic disorder therapeutics.
Industry Context
180 Life Sciences Corp. operates in Cryptocurrency Treasury/Digital Asset Accumulation & Legacy Biotechnology IP.
Key facts
Founded: Prior as 180 Life Sciences biotech; rebranded 2025 as ETHZilla · Headquarters: Palo Alto, California · Employees: Not available · Revenue: Not disclosed for crypto operations · Market cap: ~$1.1B (October 2025 data)